The MSG Titans Diverge: AI Reshapes the Traditional Seasoning Industry Landscape

Introduction: Same Starting Line, Two Destinies

In the long history of China's seasoning industry, Meihua Biology and Lotus Health were once hailed as the "Twin Titans of MSG," together commanding half of the domestic monosodium glutamate market. Yet by 2025, the fortunes of these two companies could not be more different — Meihua Biology's market capitalization has surpassed 50 billion yuan, firmly establishing it as the global leader in amino acids, while Lotus Health continues to struggle in a quagmire of consecutive losses and asset restructuring.

One "switched to feeding pigs," applying amino acid products on a massive scale to the animal nutrition sector. The other "stayed at the stove," still relying on traditional MSG as its core revenue source. These two starkly different paths reflect the strategic choices facing traditional manufacturers amid the wave of AI and biotechnology.

The Real Divergence Lies in Product Structure

On the surface, the gap between the two companies is reflected in their financial statements, but the real divergence lies in their product structures.

Meihua Biology initiated its strategic transformation from a "seasoning company" to a "biomanufacturing platform" over a decade ago. Today, its MSG business accounts for less than 30% of revenue, replaced by high-value-added product lines including animal nutrition amino acids (lysine, threonine, etc.), pharmaceutical-grade amino acids, and functional food ingredients. The company has become the world's largest lysine producer, with products widely used in livestock and poultry feed — hence the moniker "switched to feeding pigs."

In contrast, Lotus Health's MSG and seasoning business has consistently dominated its revenue. Although the company has attempted to expand into health foods and e-commerce channels, its core product structure has undergone virtually no substantive change. Against the backdrop of shrinking overall demand and overcapacity in the MSG industry, the "staying at the stove" strategy has trapped it in a vicious cycle of price wars.

AI and Biotechnology: Meihua Biology's "Invisible Engine"

Meihua Biology's successful transformation was not simply a matter of business diversification. Behind it lies a comprehensive digital intelligence system powered by AI and biotechnology.

Intelligent Fermentation Optimization. The core process in amino acid production is microbial fermentation, which involves the dynamic regulation of dozens of parameters including temperature, pH, dissolved oxygen levels, and feeding strategies. Meihua Biology has introduced a machine learning-based fermentation process optimization system. Through deep analysis of massive volumes of historical fermentation data, the AI model can predict fermentation trends in real time and automatically adjust process parameters, boosting fermentation efficiency by 15%–20% while significantly reducing energy consumption and raw material waste.

AI-Driven Strain Breeding. Traditional strain improvement relies on random mutation and manual screening — a process that is both time-consuming and inefficient. Meihua Biology has partnered with multiple research institutions to leverage AI-assisted genomic analysis and metabolic flux prediction technologies, dramatically accelerating the directed breeding of high-yield strains. According to publicly available information, the acid-producing capacity of its core strains has undergone multiple rounds of iterative upgrades over the past five years.

Smart Manufacturing and Digital Twins. On the production side, Meihua Biology's major production bases have achieved a high degree of automation, deploying Industrial Internet of Things (IIoT) sensor networks and digital twin systems. Through real-time monitoring and simulation of the entire production process, management can test process improvement plans in a virtual environment before deploying validated solutions to actual production lines, greatly reducing the cost of trial and error.

Intelligent Supply Chain Decision-Making. Facing the globalized animal nutrition market, Meihua Biology uses AI predictive models to conduct comprehensive analysis of bulk raw material prices, downstream farming cycles, international trade policies, and other factors to optimize procurement and sales timing. This data-driven supply chain management capability has enabled the company to maintain relatively stable profitability even amid fluctuations in the hog cycle.

Lotus Health's Predicament: Not Unwilling to Transform, but Unable To

It would be unfair to attribute Lotus Health's predicament simply to "strategic missteps." In fact, the company has made multiple transformation attempts, but has been constrained by numerous factors and has never been able to break through the bottleneck.

Insufficient Technology Accumulation. Moving from MSG to animal nutrition amino acids may seem to fall within the same domain of fermentation industry, but there are qualitative differences in the requirements for strain technology, process control, and product purity. Lotus Health has chronically underinvested in core technology R&D, lacking the technological foundation needed to expand into high-end amino acid categories.

Weak Digital Infrastructure. While Meihua Biology was already using AI to optimize fermentation parameters, some of Lotus Health's production processes still relied on human experience. Digital transformation requires substantial upfront investment, and sustained operational pressures have made it difficult for the company to commit to long-cycle technology investments.

Heavy Historical Burdens. Years of operational difficulties have saddled Lotus Health with significant debt and legacy issues. Management's attention has been largely consumed by financial restructuring and asset disposal, making it difficult to focus on business innovation and technology upgrades.

Industry Implications: AI Is Redefining the Boundaries of "Traditional Industries"

The divergence of the MSG titans is essentially a classic case study in how traditional industries can embrace technological change. It offers several thought-provoking insights:

First, AI is not the exclusive domain of internet companies. In seemingly "unglamorous" fields like biomanufacturing, the application value of AI is equally enormous. Technologies such as intelligent fermentation, AI-assisted breeding, and digital twins are profoundly reshaping the competitive landscape of the fermentation industry, and early movers have gained efficiency advantages that are difficult to overcome.

Second, product structure transformation and technology transformation must advance in tandem. Meihua Biology's success lies not only in choosing the growth track of animal nutrition but also in building core competitiveness on that new track through AI and biotechnology. Business transformation without technological support often amounts to jumping from one red ocean into another.

Third, digital transformation has a "window of opportunity." Technology investments require time to accumulate before they translate into competitive advantages, and the earlier the deployment, the more significant the compounding effect. Once the critical window is missed, the difficulty of catching up grows exponentially for latecomers.

Outlook: Biomanufacturing + AI — The Rise of a Trillion-Dollar Track

From a broader perspective, the story of the MSG titans is merely a microcosm of the larger "AI + Biomanufacturing" wave. According to McKinsey's projections, the global biomanufacturing market could exceed one trillion dollars by 2030, with AI serving as the core driver of this growth.

Domestically, the intersection of synthetic biology and AI is attracting increasing attention and capital. From amino acids to organic acids, from bio-based materials to innovative pharmaceutical intermediates, AI-assisted microbial cell factories are reshaping production methods across multiple traditional industries including chemicals, agriculture, and pharmaceuticals.

Meihua Biology's case demonstrates that traditional fermentation companies are fully capable of achieving "second curve" growth through AI empowerment. Meanwhile, Lotus Health's predicament reminds us that in the face of technological revolution, the cost of hesitation and wait-and-see may far exceed imagination.

The story of the MSG titans continues, but the signal it sends is already clear enough — in an era where AI is reshaping everything, no industry can call itself "traditional" and remain on the sidelines.